We are live on ! Find out more
IDNA icon

iShares Genomics Immunology and Healthcare ETF

4 hedge funds and large institutions have $6.68M invested in iShares Genomics Immunology and Healthcare ETF in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

26.6% more ownership

Funds ownership: 0% → 26.6% (+27%)

Holders
4
Holders Change
+4
Holders Change %
–
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Sellers

No sellers this quarter

IDNA Hedge Fund Activity: Q2 2019 in Review

4 of the 4,627 institutional investors tracked by Wall St. Rank reported a position in iShares Genomics Immunology and Healthcare ETF (IDNA) for Q2 2019, worth a combined $6.68M.

Buyers outnumbered sellers: 4 funds opened new IDNA positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $5.26M.

  • 4 institutional investors held iShares Genomics Immunology and Healthcare ETF (IDNA) as of Q2 2019, up from 0 in Q1 2019.
  • Funds reported $6.68M of iShares Genomics Immunology and Healthcare ETF stock for Q2 2019.
  • 4 funds opened new iShares Genomics Immunology and Healthcare ETF positions in Q2 2019 and 0 closed out, a net change of +4 holders.
  • The largest iShares Genomics Immunology and Healthcare ETF buyer in Q2 2019 was BlackRock, an estimated $5.26M added.

Based on aggregated 13F filings for Q2 2019.